Serotonin mediates CA1 spine density but is not crucial for ovarian steroid regulation of synaptic plasticity in the adult rat dorsal hippocampus.
The activity of the serotonin (5-hydroxytryptamine, 5-HT) system is sensitive to estradiol and progesterone. During the ovarian cycle, dendritic spines on CA1 pyramidal neurons of the dorsal hippocampus are increased by estradiol and later decreased by progesterone. We sought to determine whether 5-HT is involved in maintaining CA1 spine density and/or in steroid regulation of synaptic plasticity in dorsal hippocampus. Ovariectomized rats were treated (sc) over 10 days with the tryptophan hydroxylase inhibitor parachlorophenylalanine (pCPA) to deplete 5-HT, followed by estradiol benzoate on days 10 and 11. A subset of animals received progesterone on day 12. The day after the last treatment, rats were perfused and brains were processed for Golgi impregnation. Separate groups were processed for radioimmunocytochemistry (RICC) for the spine-associated protein, spinophilin, or high-performance liquid chromatography (HPLC) for monoamine analysis. Golgi and RICC data indicate that CA1 apical spine density was significantly decreased by pCPA (17-20%). Estradiol increased spine density in both saline- and pCPA-treated rats compared to respective controls (30%); however, pCPA animals maintained significantly fewer spines. No differences in spine densities were observed between saline- and pCPA-treated rats given estradiol and progesterone. Depletion of 5-HT by pCPA was confirmed in the CA1 (-90%) and dorsal raphe (-80%) by HPLC analysis. While 5-HT depletion was associated with a 57% decrease in CA1 norepinephrine (NE), there was no difference in dorsal raphe NE. Thus, whereas 5-HT is involved in maintaining spine density in the adult female rat CA1, it is not crucial for steroid-mediated plasticity. 5-HT-regulated spines/synapses may represent distinct populations from those modulated by estradiol and progesterone in dorsal hippocampus.
Alves
Stephen E
SE
Atherosclerosis and Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA. stephen_alves@merck.com
Hoskin
Elena
E
Lee
Susan J
SJ
Brake
Wayne G
WG
Ferguson
Deveroux
D
Luine
Victoria
V
Allen
Patrick B
PB
Greengard
Paul
P
McEwen
Bruce S
BS
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004958:Estradiol / Q000494:pharmacology* / Q000502:physiology; D005260:Female; D006624:Hippocampus / Q000737:chemistry / Q000166:cytology* / Q000187:drug effects*; D006652:Histological Techniques; D007150:Immunohistochemistry; D008840:Microfilament Proteins / Q000032:analysis; D009419:Nerve Tissue Proteins / Q000032:analysis; D009473:Neuronal Plasticity / Q000502:physiology; D009474:Neurons / Q000737:chemistry / Q000166:cytology / Q000187:drug effects; D011374:Progesterone / Q000494:pharmacology* / Q000502:physiology; D016719:Radioimmunodetection; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000502:physiology; D014365:Tryptophan Hydroxylase / Q000037:antagonists & inhibitors; D000099273:Neurabins
D004958:Estradiol; D008840:Microfilament Proteins; D009419:Nerve Tissue Proteins; D011374:Progesterone; D012701:Serotonin; D014365:Tryptophan Hydroxylase; D000099273:Neurabins